Special Issue "New Insights into Breast and Endometrial Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 31 October 2019
Dr. Yasuhiro Miki
Department of Disaster Obstetrics and Gynecology, International Research Institute of Disaster Science (IRIDeS), Tohoku University, 2-1 Seiryo-machi, Sendai, Miyagi 9808575, Japan
Website | E-Mail
Interests: endocrine-related cancer; intracrine; cancer microenvironment; psychological stress and endocrine disruption
Cancers of the breast and endometrium are amongst the most common cancers affecting women. In many cases, it is also well known that these cancers show estrogen-dependent proliferation; therefore, hormone therapy strategies are employed. Tamoxifen is an effective hormonal therapy that is traditionally used for estrogen receptor-positive breast cancer patients. However, in endometrial cancer, it is well established that tamoxifen treatment increases the risk of poor prognosis type of endometrial cancer.
All breast cancers, except for triple-negative breast cancer (TNBC), are classified by the expression of biomarkers, such as estrogen receptor, progesterone receptor, and HER2. In TNBC patients, treatment with hormone therapy or HER2 inhibitors is ineffective; therefore, the discovery of novel therapeutic targets is crucial. Type I endometrial cancer, commonly known as an endometrioid, is a prototype estrogen-dependent tumor. Conversely, type II endometrial cancers, including serous and clear cell types, are estrogen-independent and are known to have a poor prognosis.
There are similarities and differences in the behavior of breast and endometrial cancer cells. This Special Issue will focus on recent advances in epidemiology and clinical, molecular, and biochemical research in breast and/or endometrial cancers, with the aim of expanding the understanding of these tumors.
Contributions on these related topics are welcome, including original research, case reports, and reviews. We also welcome submissions from young researchers, including postdocs and students.
Dr. Yasuhiro Miki
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.